Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis
Year: 2024
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Chronic kidney disease (CKD) is commonly complicated by anemia. Treating dialysis-dependent patients with anemia, including daprodustat and other inhibitors of prolyl hydroxylase of hypoxia-inducible factor, recombinant human erythropoietin (rhEPO), and iron supplements. We conducted this study to test our postulation; daprodustat is superior to rhEPO and other conventional treatments respecting efficacy and safety parameters. We made systematic search through PubMed, Web of Science, Scopus, and Cochrane. Seven unique trials were eventually included for systematic review; six of them with a sample size of 759 patients entered our network meta-analysis (NMA). Daprodustat 25-30 mg was associated with the greatest change in serum hemoglobin (MD=1.86, 95%CI= [1.20; 2.52]), ferritin (MD= -180.84, 95%CI= [-264.47; -97.20]), and total iron binding capacity (TIBC) (MD=11.03, 95%CI= [3.15; 18.92]) from baseline values. Dialysis-dependent patients with anemia had a significant increment in serum Hemoglobin and TIBC and a reduction in serum ferritin, in a dose-dependent manner, when administered daprodustat.
Source: Pan African Medical Journal
Authors: Hammad Ali Fadlalmola, Khaled Mohammed Al-Sayaghi, Abdulqader Abdlah Al-Hebshi, Muhanad Alhujaily, Arwa Omar Alyamani, Alaa Abdulrhman Alem, Mona Hamza Syrafi, Sarah Alem, Afrah Hassan Farhat, Fathi Abdelrazig Mohamed, Hager Hassan Abdalrahman, Mohammed Abdelkrim Abdelmalik, Neimat Mahmoud Abdalrhman, Alamin Mustafa Eltayeb
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $180
OpenAlex ID: W4392665232